Redeye comments on last week’s news from Apple, where it announced changes to iOS and the App Store ...
We cut '23e-'25e adj. EBITA by 13-10% Inflation data for Q4 suggest negative-to-neutral volume/mix T...
Good organic growth but weak margins in Q4 2024 will be a year of transition EBITDA revised down 8-1...
Q4e: Tuesday, 30 January at 8:00 CET Healthy 2024 with 6% organic growth and solid margin expansion ...
Redeye provides its comments on Scandinavian ChemoTech’s press release from earlier today.
DT reports Q4 on Feb 1. MBU may not grow much this year, yet organic SBU-driven recovery and recent ...
Svagare marknad ger avtryck i orderingången… Även om kundaktiviteten är fortsatt intensiv och den un...
Rapportkommentar Diamyds rapport för det första kvartalet 2023/2024 var i linje med våra förväntning...
Redeye comments on Ependion's Q4 2023 report, which came in slightly below on the sales level and, a...
Redeye updates our outlook after Q4 2023. XVIVO delivers improved gross margins with a softer organi...
This afternoon after market close, BankNordik issued its 2024 net profit guidance of DKK 225-255m, s...
EcoRub har idag publicerat bolagets Q4-rapport och visar på fortsatta framsteg.
Redeye comments on Evaxion’s extreme share price movement yesterday.
Redeye comments on Mestro’s launch of its Data-as-a-Service (DaaS) solution.
Redeye updates its estimates and valuation following Coala Life’s recent rights issue, securing cSEK...
Redeye believes Sdiptech’s acquisition of JR Industries looks solid.
Organic sales decline again... ...but strong margin and FCF development In good shape for eventual m...
Q4'23 results due 6 February Already pre-announced strong sales for Oct-Nov Fully focused US orthobi...
Equity analyst Markus Almerud interviews Zwipe's CEO Robert Puskaric after the announcement that the...
Chordate Medical AB (”Chordate” eller ”bolaget”) är verksamma inom medicinteknikbranschen, och bolag...
